Tags:

EyePoint, Inc.


A securities class action has been filed against EyePoint, Inc. (EYPT) on behalf of all persons who purchased or otherwise acquired EyePoint, Inc. (NASDAQ: EYPT) securities between May 27, 2025 through August 14, 2026. This case has been filed in the USDC – EDNY.

EYEPOINT INC - Class Period Stock Chart

The complaint alleges that EyePoint misled investors regarding the efficacy and viability of DURAVYU for the treatment of wet age-related macular degeneration.  During the Class Period, defendants were evaluating DURAVYU for the treatment of wet age-related macular degeneration (“wet AMD”) in EyePoint’s Phase 3 LUGANO and LUCIA trials. The primary endpoint of both trials was the average change in best corrected visual acuity (“BCVA”) at weeks 52 and 56 versus baseline.

Plaintiff alleges that defendants touted DURAVYU’s purportedly “differentiated profile,” as well as its “uniquely suited” mechanism of action and “robust” and “best-in-class” efficacy profile, purportedly demonstrated by data from other studies.

While making these positive statements, plaintiff contends that defendants failed to disclose that DURAVYU was less effective than defendants had led investors to believe and accordingly, DURAVYU’s clinical, regulatory, and commercial prospects were overstated.

Tags:

Securities